Sujit Sheth
Pediatric Hematology-Oncology · New York, NYNPI 1841263878
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $224,192 of the $358,718 with a category attached, or 62.5%. 11 manufacturers reported payments, led by Agios Pharmaceuticals, Inc. at 37.9% of the total. 2025 is the largest year on record at $84,313, 2.0 times the $41,739 reported in 2019. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $1546.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$136K
- Bristol Myers Squibb$80K
- Vertex$76K
- E.r. Squibb & Sons, L.L.C.$32K
- Chiesi USA, Inc.$17K
- Novo Nordisk Health Care AG$8K
- plus $9K from 5 others
Across 73 payments — averaging $9375.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$195K
- Agios Pharmaceuticals, Inc.$190K
- Terumo BCT, Inc.$74K
- Novartis$54K
- Regeneron$46K
- E.r. Squibb & Sons, L.L.C.$35K
- plus $91K from 4 others
What the payments were for
- Consulting fees$224,19262%
- Speaking & faculty fees$61,10417%
- Grants$2,5001%
- Travel & lodging$59,37717%
- Food & beverage$5,9002%
- Education$5,6452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 98 | $135,981 |
| Bristol Myers Squibb | 46 | $80,187 |
| Vertex | 52 | $75,838 |
| E.r. Squibb & Sons, L.L.C. | 14 | $32,239 |
| Chiesi USA, Inc. | 12 | $17,375 |
| Novo Nordisk Health Care AG | 3 | $7,653 |
| Acceleron Pharma, Inc. | 2 | $5,940 |
| Octapharma USA, Inc. | 1 | $2,500 |
| Mckesson Corporation | 1 | $530 |
| Genentech USA, Inc. | 2 | $350 |
| Apo-pharma Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$358,718 in reported general payments places this provider in the 95th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in New York
- Jaap Jan BoelensNew York$303K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- James FerraraNew York$118K
- John LevineNew York$98K
- Nai-Kong CheungNew York$86K
- Andrew HarrisNew York$85K
- Joseph OvedNew York$77K
- Catherine McGuinnNew York$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.